Communicating dermatologic drug safety: a comparative evaluation of United States and United Kingdom pharmacovigilance systems using dapsone as a model medication

PURPOSE: Postmarketing pharmacovigilance systems are essential for identifying adverse drug reactions (ADRs) that may not be recognized during premarketing clinical trials. Although the United States Food and Drug Administration (FDA) Adverse Event Monitoring System (AEMS) and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme share the common objective of medication safety surveillance, little is known about how these systems differ in organizing and communicating postmarketing safety information to clinicians. This study compared the clinician-facing organization, accessibility, and communication of postmarketing safety information between the FDA AEMS Public Dashboard and the MHRA Yellow Card Interactive Drug Analysis Profile (iDAP) using dapsone as a representative dermatologic medication. METHODS: A cross-sectional comparative pharmacovigilance study was conducted using publicly available FDA AEMS and MHRA Yellow Card data extracted on June 29, 2026. Descriptive analyses characterized adverse-event reports, patient demographics, clinical outcomes, MedDRA Preferred Terms, and System Organ Class distributions. The two pharmacovigilance platforms were qualitatively compared using a predefined framework assessing data accessibility, organization, clinical usability, and research utility. RESULTS: The FDA AEMS identified 4,793 reports associated with dapsone-containing products, including 3,686 (76.9%) classified as serious and 280 (5.8%) reporting death. The MHRA Yellow Card Scheme identified 699 reports comprising 1,701 adverse reactions, including 559 (80.0%) serious reports and 25 (3.6%) fatal outcomes. Both systems demonstrated overlapping patterns of reported adverse reactions. Despite similar pharmacovigilance outputs, substantial differences were observed in the communication of safety information. The FDA emphasized downloadable datasets, customizable searches, and case-level transparency to facilitate secondary pharmacovigilance analyses, whereas the MHRA prioritized standardized, drug-specific summaries, hierarchical MedDRA organization, integrated visualizations, and contextual guidance to support rapid clinical interpretation. CONCLUSIONS: The FDA AEMS and MHRA Yellow Card Scheme identify similar postmarketing safety profiles for dapsone while employing distinct approaches to communicating pharmacovigilance information. These complementary strengths suggest that future clinician-facing pharmacovigilance platforms should integrate the analytical flexibility of the FDA with the standardized, medication-specific communication strategies of the MHRA to improve the translation of postmarketing safety data into dermatology practice while preserving scientific transparency.

Authors

Institutions

Publication Details

Journal
European Journal of Clinical Pharmacology
Published
2026-11-21
DOI
https://doi.org/10.1007/s00228-026-04231-3
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Communicating dermatologic drug safety: a comparative evaluation of United States and United Kingdom pharmacovigilance systems using dapsone as a model medication

S Burstein, Howard I. Maïbach
European Journal of Clinical Pharmacology
Pharmacovigilance and Adverse Drug Reactions
article

Communicating dermatologic drug safety: a comparative evaluation of United States and United Kingdom pharmacovigilance systems using dapsone as a model medication

S Burstein, Howard I. Maïbach
article en

Abstract

PURPOSE: Postmarketing pharmacovigilance systems are essential for identifying adverse drug reactions (ADRs) that may not be recognized during premarketing clinical trials. Although the United States Food and Drug Administration (FDA) Adverse Event Monitoring System (AEMS) and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme share the common objective of medication safety surveillance, little is known about how these systems differ in organizing and communicating postmarketing safety information to clinicians. This study compared the clinician-facing organization, accessibility, and communication of postmarketing safety information between the FDA AEMS Public Dashboard and the MHRA Yellow Card Interactive Drug Analysis Profile (iDAP) using dapsone as a representative dermatologic medication. METHODS: A cross-sectional comparative pharmacovigilance study was conducted using publicly available FDA AEMS and MHRA Yellow Card data extracted on June 29, 2026. Descriptive analyses characterized adverse-event reports, patient demographics, clinical outcomes, MedDRA Preferred Terms, and System Organ Class distributions. The two pharmacovigilance platforms were qualitatively compared using a predefined framework assessing data accessibility, organization, clinical usability, and research utility. RESULTS: The FDA AEMS identified 4,793 reports associated with dapsone-containing products, including 3,686 (76.9%) classified as serious and 280 (5.8%) reporting death. The MHRA Yellow Card Scheme identified 699 reports comprising 1,701 adverse reactions, including 559 (80.0%) serious reports and 25 (3.6%) fatal outcomes. Both systems demonstrated overlapping patterns of reported adverse reactions. Despite similar pharmacovigilance outputs, substantial differences were observed in the communication of safety information. The FDA emphasized downloadable datasets, customizable searches, and case-level transparency to facilitate secondary pharmacovigilance analyses, whereas the MHRA prioritized standardized, drug-specific summaries, hierarchical MedDRA organization, integrated visualizations, and contextual guidance to support rapid clinical interpretation. CONCLUSIONS: The FDA AEMS and MHRA Yellow Card Scheme identify similar postmarketing safety profiles for dapsone while employing distinct approaches to communicating pharmacovigilance information. These complementary strengths suggest that future clinician-facing pharmacovigilance platforms should integrate the analytical flexibility of the FDA with the standardized, medication-specific communication strategies of the MHRA to improve the translation of postmarketing safety data into dermatology practice while preserving scientific transparency.

European Journal of Clinical PharmacologyVol. 82(12)
University of California, San Francisco (US), East Carolina University (US)
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon